Sotorasib, known as Lumakras, is a KRAS G12C inhibitor and the first medicine in its class to reach the clinic, with FDA accelerated approval in 2021 for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer after prior therapy. It is supplied as 120 mg tablets taken once daily. For B2B buyers, the sourcing challenge is less about the chemistry and more about qualifying a supplier who can prove origin, storage, and the right documentation.
Buyers should verify the manufacturer or authorized distributor, request a certificate of analysis, and confirm the product matches the registered marketing authorization in the destination market. Because sotorasib is a prescription oncology drug, legitimate supply depends on proper licensing at every step. Asking for batch traceability and the cold-chain log protects the buyer if a quality question later arises.
Although sotorasib tablets are stored at controlled room temperature in their commercial presentation, transit still needs protection from heat and moisture to keep the pack intact. Sealed, labeled cartons with visible batch numbers support recall readiness and audit trails. Distributors who document each handoff reduce the risk of a broken chain that could compromise a high-value oncology product. A simple incoming inspection at the warehouse catches damaged or mislabeled packs before they reach the clinic.
Sotorasib only works in tumors that carry the KRAS G12C mutation, so a companion diagnostic must confirm the mutation before therapy. Tests such as Guardant360 CDx and the QIAGEN therascreen KRAS RGQ PCR kit are used for this purpose. Buyers supporting a treatment program should plan for both the drug and the mutation test, because one is useless without the other.
Q: What is sotorasib used for in B2B supply? A: It is a KRAS G12C inhibitor for adults with KRAS G12C-mutated advanced non-small cell lung cancer after prior therapy, supplied as 120 mg tablets for qualified oncology channels.
Q: Why is a companion diagnostic part of sourcing? A: The drug only benefits patients whose tumor carries KRAS G12C, so a validated mutation test such as Guardant360 CDx must confirm eligibility before therapy begins.
Q: What documents prove a legitimate supply? A: A certificate of analysis, the supplier's license, batch traceability, and alignment with the local marketing authorization are the core documents a buyer should require.
Sotorasib, known as Lumakras, is a KRAS G12C inhibitor and the first medicine in its class to reach the clinic, with FDA accelerated approval in 2021 for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer after prior therapy. It is supplied as 120 mg tablets taken once daily. For B2B buyers, the sourcing challenge is less about the chemistry and more about qualifying a supplier who can prove origin, storage, and the right documentation.
Buyers should verify the manufacturer or authorized distributor, request a certificate of analysis, and confirm the product matches the registered marketing authorization in the destination market. Because sotorasib is a prescription oncology drug, legitimate supply depends on proper licensing at every step. Asking for batch traceability and the cold-chain log protects the buyer if a quality question later arises.
Although sotorasib tablets are stored at controlled room temperature in their commercial presentation, transit still needs protection from heat and moisture to keep the pack intact. Sealed, labeled cartons with visible batch numbers support recall readiness and audit trails. Distributors who document each handoff reduce the risk of a broken chain that could compromise a high-value oncology product. A simple incoming inspection at the warehouse catches damaged or mislabeled packs before they reach the clinic.
Sotorasib only works in tumors that carry the KRAS G12C mutation, so a companion diagnostic must confirm the mutation before therapy. Tests such as Guardant360 CDx and the QIAGEN therascreen KRAS RGQ PCR kit are used for this purpose. Buyers supporting a treatment program should plan for both the drug and the mutation test, because one is useless without the other.
Q: What is sotorasib used for in B2B supply? A: It is a KRAS G12C inhibitor for adults with KRAS G12C-mutated advanced non-small cell lung cancer after prior therapy, supplied as 120 mg tablets for qualified oncology channels.
Q: Why is a companion diagnostic part of sourcing? A: The drug only benefits patients whose tumor carries KRAS G12C, so a validated mutation test such as Guardant360 CDx must confirm eligibility before therapy begins.
Q: What documents prove a legitimate supply? A: A certificate of analysis, the supplier's license, batch traceability, and alignment with the local marketing authorization are the core documents a buyer should require.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
